<<

l.The AI.LHAT Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT) II JAMA. - 2002. - 288. - P. 2981-97.

l.Lindholm L. H Persson M., Alaupovic P.

et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) // Hypertension. 2003. 21, P.563-74.

3. Gress T. W., Nieto F. /., Shahar E. et al. Hypertension and anthihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study // New Engl. J. Med. 2000. 342. P. 905-12.

4. Moser M. Clinical management of hypertension. 4th edition. Professional Communications, Inc., 1999.

b.Pollare T, Lithell H., Selinus I. et al. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension // Diabetologia. 1988. 31. P.415-20.

6. Brown M. /., Palmer C.

R., Castaigne A. et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. 2000. N 356. P. 366-72.

7. Black H. R., Elliott IV. /., Grandits G. et al. CONVINCE Research group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial // JAMA. 2003. 289. P. 2073-82.

8. Pepine C. Hanberg E. M., Cooper-DeHoff R. M. et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The Intrenational Verapamil-Trandolapril Study (INVEST); a randomized controlled trial // JAMA.

2003. 290. P. 2805-16.

9. Lau , Carlsson . ., Leung . S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets // Diabetologia. 2004. 47. P. 240-8.

10. Tikellis C Wookey P, Candido R. Improved islet morphology after blockade of the ren- nin-angiotensin system in the ZDF rat II Diabetes. 2004. N 53. P. 989-97.

1 l.Folli E, Saad M. J. A., Velloso L. et al. Crosstalk between insulin and angiotensin II signaling systems // Exp. Clin. Endocrinol. Diabetes. 1999. 107. P. 133-9.

12. Kudoh A., Malsuki A. Effects of angiotensin-converting enzyme inhibitors on glucose uptake // Hypertension. 2000. Ne 36. P. 239-44.

13. Nawano M Anai M., Funaki M. et al. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat // Metabolism. 1999. 48. P. 1248-55.

14. Julius S., Kjeldsen S. E Weber M. Outcomes in hypertensive patientrs at high cardiovascular risk trated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. 2004. 363. P. 2022-31.

15. Benson S. G, Pershadsingh FI. A., Ho C. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARy-modulating activity //

<< |
: .., ... . .: - 26 ,2006 344 .: ., .. 2006

:

  1. :
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
- - - - - - - - - - - - -